Corbus Pharmaceuticals Holdings IncCRBP
Price$6.34

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$101.9MTTM through 30 Jun 2026
Free Cash Flow -$86.7MTTM through 30 Jun 2026

Margins

Current
Gross Margin0.0%

Returns

-99.7%ROE
-29.1%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio7.92x
Net Debt-$138.2Mnet cash position
Cash & Equivalents$23.4M

Quality Metrics

Altman Z-Score-4.89
Piotroski F-Score1 / 9
Earnings-Beat Rate25.0%

Multi-Year Trend

Revenue
'18'19'20'21'22
FY2022: $0
Diluted EPS-$6.11TTM
'21'22'23'24'25
FY2025: $-5.90

Dividend

No dividend

Capital Allocation

R&D Spend$90.3M

Segment Performance

SegmentRevenueYoYOutlook
Clinical-Stage Biopharmaceuticals$0
View details

Topline 16-week data for the CANYON-1 obesity study of CRB-913 is expected in summer 2026, and registrational TEMPO-1 trial for CRB-701 in 2L OPSCC is on track to initiate in summer 2026.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.